drugset / Trial / NCT01302119

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

NCT01302119 ↗

Phase 3 Completed 604 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.

Timeline

Start
2011-02
Primary completion
2012-12-31
Completion
2013-02-20

Outcome

Met primary endpoint

registry analysis (superiority or other test); AN2690 Topical Solution, 5% vs Solution Vehicle; p <0.001; Cochran-Mantel-Haenszel NCT01302119 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tavaborole Small molecule 5 % Topical